Real-World Experience Treating Pediatric Epilepsy Patients With Cenobamate
IntroductionIn one third of all patients with epilepsy, seizure freedom is not achieved through anti-seizure medication (ASM). These patients have an increased risk of earlier death, poorer cognitive development, and reduced quality of life. Cenobamate (CNB) has recently been approved as a promising...
Main Authors: | Konstantin L. Makridis, Thomas Bast, Christine Prager, Tatjana Kovacevic-Preradovic, Petra Bittigau, Thomas Mayer, Eva Breuer, Angela M. Kaindl |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-07-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2022.950171/full |
Similar Items
-
Cenobamate significantly improves seizure control in intellectually disabled patients with drug-resistant epilepsy and allows drug load reduction
by: Anna-Lena Friedo, et al.
Published: (2023-07-01) -
Case Report: Behavioral Disorder Following Hemispherotomy: A Valproate Effect?
by: Konstantin L. Makridis, et al.
Published: (2021-11-01) -
Cenobamate (YKP3089) and Drug-Resistant Epilepsy: A Review of the Literature
by: Jamir Pitton Rissardo, et al.
Published: (2023-07-01) -
Safety and efficacy of cenobamate in patients with uncontrolled focal seizures - a review of the literature
by: Zofia Pietrzak, et al.
Published: (2022-02-01) -
Corticosteroids in childhood epilepsies: A systematic review
by: Lena-Luise Becker, et al.
Published: (2023-03-01)